Literature DB >> 14702042

Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice.

Geng Liu1, John M Parant, Gene Lang, Patty Chau, Arturo Chavez-Reyes, Adel K El-Naggar, Asha Multani, Sandy Chang, Guillermina Lozano.   

Abstract

The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream genes. At the cellular level, p53 induces apoptosis, cell cycle arrest and senescence. A rare mutant form of p53 with the amino acid substitution R175P, found in human tumors, is completely defective in initiating apoptosis but still induces cell cycle arrest. To decipher the functional importance of these pathways in spontaneous tumorigenesis, we used homologous recombination to generate mice with mutant p53-R172P (the mouse equivalent of R175P in humans). Mice inheriting two copies of this mutation (Trp53(515C/515C)) escape the early onset of thymic lymphomas that characterize Trp53-null mice. At 7 months of age, 90% of Trp53-null mice had died, but 85% of Trp53(515C/515C) mice were alive and tumor-free, indicating that p53-dependent apoptosis was not required for suppression of early onset of spontaneous tumors. The lymphomas and sarcomas that eventually developed in Trp53(515C/515C) mice retained a diploid chromosome number, in sharp contrast to aneuploidy observed in tumors and cells from Trp53-null mice. The ability of mutant p53-R172P to induce a partial cell cycle arrest and retain chromosome stability are crucial for suppression of early onset tumorigenesis.

Entities:  

Mesh:

Year:  2003        PMID: 14702042     DOI: 10.1038/ng1282

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  132 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  Suppression of tumorigenesis by the p53 target PUMA.

Authors:  Michael T Hemann; Jack T Zilfou; Zhen Zhao; Darren J Burgess; Gregory J Hannon; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

3.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

4.  The ups and downs of p53 regulation in hematopoietic stem cells.

Authors:  Hussein A Abbas; Vinod Pant; Guillermina Lozano
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

5.  Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.

Authors:  Sergio Acin; Zhongyou Li; Olga Mejia; Dennis R Roop; Adel K El-Naggar; Carlos Caulin
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

Review 6.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

7.  IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis.

Authors:  R Kibe; S Zhang; D Guo; L Marrero; F Tsien; P Rodriguez; S Khan; A Zieske; J Huang; W Li; S K Durum; T Iwakuma; Y Cui
Journal:  Cell Death Differ       Date:  2012-01-27       Impact factor: 15.828

8.  Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression.

Authors:  Connie Chao; Deron Herr; Jerold Chun; Yang Xu
Journal:  EMBO J       Date:  2006-06-01       Impact factor: 11.598

9.  Apoptotic actions of p53 require transcriptional activation of PUMA and do not involve a direct mitochondrial/cytoplasmic site of action in postnatal cortical neurons.

Authors:  Takuma Uo; Yoshito Kinoshita; Richard S Morrison
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 10.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.